title: Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes.
abstract: BACKGROUND
  Comorbid neurobehavioral disturbances and type-2 diabetes mellitus (T2DM) warrant immediate research attention. Exenatide, which is a potent and selective agonist for the glucagon-like peptide-1 (GLP-1), is used in the treatment of T2DM. Exenatide displays a multitude of effects in the central nervous system. The aim of this study was to investigate the anxiolytic- and antidepressant-like effects and analgesic effects of exenatide in a type-2 diabetic mouse model.
  
  
  METHODS
  Modified elevated plus-maze test for anxiolytic-like, forced swimming test for depression-like behavior and hotplate test for neuropathy were used as behavioral tasks. Behavioral parameters were investigated in a streptozocin--(100 mg/kg, i.p.) and nicotinamide--(240 mg/kg, i.p.) induced type-2 diabetic mouse model. Exenatide (0.1 µg/kg, s.c., twice daily) was administered for 2 weeks. Vehicle (control), diabetic, and exenatide-treated diabetic mice were tested.
  
  
  RESULTS
  Our results confirm that exenatide exerts anxiolytic- and antidepressant-like effects and might be effective in diabetic neuropathy in a diabetic mouse model.
  
  
  CONCLUSIONS
  Exenatide may be a good candidate as a treatment option for depression, anxiety, and neuropathy in patients with type-2 diabetes.
authors: Department of Medical Pharmacology, Psychopharmacology Lab, Medical Faculty, Kocaeli University, Kocaeli, Turkey.
authors: Ipek
authors: I
authors: Komsuoglu Celikyurt
authors: Department of Medical Pharmacology, Psychopharmacology Lab, Medical Faculty, Kocaeli University, Kocaeli, Turkey.
authors: Oguz
authors: O
authors: Mutlu
authors: Department of Medical Pharmacology, Psychopharmacology Lab, Medical Faculty, Kocaeli University, Kocaeli, Turkey.
authors: Guner
authors: G
authors: Ulak
authors: Department of Medical Pharmacology, Medical Faculty, Dicle University, Diyarbakır, Turkey.
authors: Emre
authors: E
authors: Uyar
authors: Department of Medical Pharmacology, Psychopharmacology Lab, Medical Faculty, Kocaeli University, Kocaeli, Turkey.
authors: Emine
authors: E
authors: Bektaş
authors: Department of Medical Pharmacology, Psychopharmacology Lab, Medical Faculty, Kocaeli University, Kocaeli, Turkey.
authors: Furuzan
authors: F
authors: Yildiz Akar
authors: Department of Medical Pharmacology, Psychopharmacology Lab, Medical Faculty, Kocaeli University, Kocaeli, Turkey.
authors: Faruk
authors: F
authors: Erden
authors: Department of Endocrinology and Metabolism, Medical Faculty, Kocaeli University, Kocaeli, Turkey.
authors: Ilhan
authors: I
authors: Tarkun
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000503:physiopathology; D004195:Disease Models, Animal; D000077270:Exenatide; D007103:Immobilization; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D008807:Mice, Inbred BALB C; D009043:Motor Activity / Q000187:drug effects; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D011930:Reaction Time / Q000187:drug effects; D013997:Time Factors; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide